STAT

JANUARY 4, 2023

Pregnancy, for the average person, is an exercise of extremes — swelling body, welling emotions, surging hormones. For people with chronic conditions and other disabilities, the experience can be even more jarring, full of additional barriers, stigma, and risks. But it’s not just pregnancy. In the United States, disabled people are less likely to be taught comprehensive sexual education and given access to contraceptives, and are more likely to have unintended pregnancies.

363

363

PharmaVoice

JANUARY 3, 2023

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

280

280

pharmaphorum

JANUARY 6, 2023

Google and DeepMind have developed an artificial intelligence-powered chatbot tool called Med-PaLM designed to generate “safe and helpful answers” to questions posed by healthcare professionals and patients. The tool is an example of a large language model or LLM, which are designed to understand queries and generate text responses in plain language, drawing from large and complex datasets – in this case, medical research.

136

136

Pharmaceutical Technology

JANUARY 6, 2023

While the treatment options for multiple sclerosis (MS) patients are growing each year with the approval of new agents, all of the currently marketed treatments only slow the disease’s progression and sometimes carry risks of severe side effects, such as liver failure or the development of viral infections. However, new mechanisms of action (MoAs) are in constant development, with some of the more innovative ones utilizing cell-based therapies.

115

115

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JANUARY 3, 2023

A diverse and inclusive workforce benefits science and research. But unless it includes people living with a disability — the largest minority group in the U.S. and around the world — research will never be fully representative and science will not reach its full potential. Although 27% of U.S. adults live with a disability, only 10% of science, engineering, and health doctorate holders, and less than 2% of researchers funded by the National Institutes of Health, report having a di

347

347

PharmaVoice

JANUARY 5, 2023

As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

246

246

PharmaTech

JANUARY 3, 2023

Advancing the use of AI to understand the whole of a disease can reveal drug development insights that lead to drug discovery breakthroughs.

Drug Development 122

Drug Development 122

STAT

JANUARY 5, 2023

SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies to treat autoimmune diseases and cancer, is now planning to cut back on both jobs and experimental drugs after an early end to a deal with Janssen. The setback, announced Thursday, will cut the company’s size to 220 workers by the end of the first quarter of this year.

Immunity 307

Immunity Immunization 307

PharmaVoice

JANUARY 4, 2023

How charitable firms such as Advancium are helping to right the market wrongs of drug development.

Drug Development 257

Drug Development 257

Pharma Times

JANUARY 4, 2023

AstraZeneca trial will study activity of AZD5156 which includes monoclonal antibody discovered by RQ Bio

131

131

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

JANUARY 3, 2023

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year. The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months.

Labelling 104

Labelling Drug Development 104

STAT

JANUARY 4, 2023

Continuing economic uncertainty and the threat of a recession are casting a pall over health tech in 2023 — a dramatic shift for an industry that enjoyed abundant funding in the pandemic’s early stages. Last quarter’s string of layoffs at companies like Ro, Noom and ThirtyMadison portend tight budgets and conservative contracts this year, with employers unsure about which digital offerings actually drive down health care costs for workers.

309

309

PharmaVoice

JANUARY 5, 2023

Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.

246

246

PharmExec

JANUARY 6, 2023

A chat with with Indegene's Timothy Moore, Senior Vice President, Emerging Biotech and Key Accounts and Jack Mycka, Vice President, Enterprise Medical Solutions and Emerging Biotech.

98

98

pharmaphorum

JANUARY 3, 2023

Research advises against aggressive cancer treatment at the end-of-life stages of the disease. At the same time, the pharmaceutical industry is creating a greater number of oncology treatments that could provide breakthroughs for patients where none previously existed. Ben Hargreaves examines why there is no easy answer to the question of when palliative care is the right option for patients.

Chemotherapy 101

Chemotherapy Immunity Immunization Hospitals 101

STAT

JANUARY 4, 2023

Walgreens plans to seek certification to begin providing abortion pills under new Food and Drug Administration rules that allow the drugs to be distributed by retail pharmacies, the company told STAT on Wednesday.  “We are working through the registration, necessary training of our pharmacists, as well as evaluating our pharmacy network in terms of where we normally dispense products that have extra FDA requirements and will dispense these consistent with federal and state laws,

285

285

PharmaVoice

JANUARY 3, 2023

A preview of the top trends on the minds of industry and market leaders for the new year.

240

240

Drug Patent Watch

JANUARY 2, 2023

Annual Drug Patent Expirations for TOVIAZ Toviaz is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent expiration for Pfizer drug TOVIAZ appeared first on DrugPatentWatch - Make Better Decisions.

98

98

pharmaphorum

JANUARY 6, 2023

With the US economy teetering on a recession, sales and marketing budgets are expected to take a hit among businesses across sectors. The pharmaceutical industry is no exception. When any organisation looks to slash its budget, the old adage about acquiring new customers costing five times as much as retaining existing customers becomes an alluring data point.

Diabetes 99

Diabetes Pharmaceutical Companies Pharmaceutical Companies 99

STAT

JANUARY 3, 2023

The number of people in the United States hospitalized with Covid-19 is about to surpass the figure reached during this summer’s spike, federal data show , as a confluence of factors — from the continued evolution of the coronavirus to holiday gatherings — drives transmission. Notably, the number of people hospitalized with Covid — roughly 40,000 — is still far below the winter waves of 2020-2021 and 2021-2022 (the wave driven by the original Omicron variant) a

Hospitals 251

Hospitals 251

PharmaVoice

JANUARY 4, 2023

The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.

130

130

Med Ed 101

JANUARY 1, 2023

Opioids are commonly used in clinical practice. Selection on these agents can often be confusion. We’ve outlined some of the most important pharmacokinetic, pharmacogenomic, and dosage form clinical pearls in the table below. For easier reading, we have also created the Opioid Comparison Table as a free downloadable PDF which you can download at the […].

Dosage 98

Dosage 98

pharmaphorum

JANUARY 4, 2023

More than 30 years after it was first formed, Geron is on the cusp of bringing its first product to market, after imetelstat hit the mark in a phase 3 trial in patients with myelodysplastic syndromes (MDS). The Foster City, California-based biotech said today that its IMerge trial of imetelstat – vying to become the first telomerase inhibitor to reach the market – hit its objectives in patients with lower risk MDS, a rare group of bone marrow cancers.

98

98

STAT

JANUARY 6, 2023

The Food and Drug Administration on Friday approved a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease. The drug, called Leqembi, was developed by Eisai , the Japanese pharmaceutical company that also developed the first symptomatic treatment for Alzheimer’s 25 years ago.

Pharmaceutical Companies 246

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 246

PharmaVoice

JANUARY 6, 2023

Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

130

130

European Pharmaceutical Review

JANUARY 6, 2023

The US Food and Drug Administration (FDA) has granted priority review for glofitamab, Roche’s CD20xCD3 T-cell engaging bispecific antibody. The decision for the FDA priority review of glofitamab is for adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. If approved, the cancer immunotherapy would be the first fixed-duration, off-the-shelf CD20xCD3 T-cell engaging bispecific antibody available for individuals with an aggressive

97

97

Drug Channels

JANUARY 4, 2023

Time for the Drug Channels annual reality check on drug pricing. The data once again tell a different story than you might read in your favorite politician’s Twitter feed or misleading news reports. For 2022, brand-name drugs’ net prices dropped for an unprecedented fifth consecutive year. What’s more, after adjusting for overall inflation, brand-name drug net prices plunged by almost 9%.

Drug Pricing 95

Drug Pricing 95

STAT

JANUARY 5, 2023

As 2023 begins, health care providers in the United States must make health records more easily available or risk losing Medicare funding under the 21st Century Cures Act. While this is a win for patients, providers, and researchers, the legislation’s failure to include dental care ignores the crucial link between oral health and overall health.

240

240

Pharmaceutical Technology

JANUARY 5, 2023

Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. Under the multi-year strategic partnership, Prevail will detect and advance capsids, which are clinically translatable, along with its cargo to develop the transformative genetic medicines by using Capsida’s novel adeno-associated virus (AAV) engineering platform.

Communication 95

Communication 95

European Pharmaceutical Review

JANUARY 4, 2023

EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead Sciences, Inc, enabling EVOQ to potentially receive up $658.5 million. The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation. “Despite key advances over the past two decades, there remains significant unmet need for people living with inflammatory and autoimmune diseases,” stated Dr Flavius

Immunity 95

Immunity Immunization 95

The Guardian - Pharmaceutical Industry

JANUARY 4, 2023

Pharmacy leaders cite ministers’ ‘lack of planning’ amid problems obtaining common products A shortage of cough and cold medicines in the UK is a result of ministers’ “lack of planning”, according to pharmacy leaders. Rishi Sunak’s Conservatives were accused of “being in denial” as supply chain problems worsen, with pharmacists reporting shortages of once-common cold and flu medicines.

95

95

STAT

JANUARY 4, 2023

China is underreporting deaths from Covid-19, a senior official of the World Health Organization said Wednesday as he urged use of a broader definition that would more fully capture the mortality impact of the country’s first big wave of Covid infection. Mike Ryan, head of the WHO’s health emergencies program, stressed that doctors and nurses should not be discouraged from reporting Covid cases and deaths.

240

240

Pharma Pathway

JANUARY 4, 2023

Ipca Laboratories Ltd- Openings for Production/ Engineering Department -Apply Now. Job Description. We are Searching Experience holder Candidates in Production/ Engineering Departments @ Ipca Laboratories. Department: Production/ Engineering. Posts: Officer/ Sr. Officer. Qualification: B.Pharm/ B.E/ B.Tech. Experience: 04-06 years/ 2 to 4 years. Location: Piparia, Silvassa.

94

94

Pharma Times

JANUARY 5, 2023

Agreement covers cell-based studies, with an additional option to further develop screening activities

118

118

PharmExec

JANUARY 5, 2023

Using market access data from day one of your drug development and commercialization journey puts your brand in the best position to succeed at launch.

Drug Development 98

Drug Development 98